“Like a pickle that’s been unpickled”: Emotional, identity and behavioural transformations throughout hepatitis C treatment
暂无分享,去创建一个
[1] M. Hellard,et al. Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study , 2021, Harm Reduction Journal.
[2] M. Hellard,et al. Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs , 2021, Journal of viral hepatitis.
[3] M. Hellard,et al. Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study. , 2020, The International journal on drug policy.
[4] G. Fitzgerald,et al. ‘I’m over the moon!’: patient-perceived outcomes of hepatitis C treatment , 2020 .
[5] P. Carrieri,et al. Life after hepatitis C cure in HIV‐infected people who inject drugs and men who have sex with men treated with direct‐acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH) , 2020, Journal of Viral Hepatitis.
[6] Narelle Warren,et al. Post-cure , 2020, Medicine Anthropology Theory.
[7] T. Rhodes,et al. How to think with models and targets: Hepatitis C elimination as a numbering performance. , 2020, The International journal on drug policy.
[8] M. Hellard,et al. Australia needs to increase testing to achieve hepatitis C elimination , 2020, The Medical journal of Australia.
[9] T. Rhodes,et al. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination. , 2020, The International journal on drug policy.
[10] M. Hellard,et al. Treatment access is only the first step to hepatitis C elimination: experience of universal anti‐viral treatment access in Australia , 2019, Alimentary pharmacology & therapeutics.
[11] M. Hellard,et al. FRI-228-Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention) study , 2019, Journal of Hepatology.
[12] A. Gifford,et al. Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes , 2019, BMC Health Services Research.
[13] M. Hellard,et al. Improving hepatitis C direct‐acting antiviral access and uptake: A role for patient‐reported outcomes and lived experience , 2018, Journal of viral hepatitis.
[14] C. Treloar,et al. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia , 2018, Harm Reduction Journal.
[15] M. Hellard,et al. Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia , 2018, Hepatology, Medicine and Policy.
[16] L. Elliott,et al. Hepatitis C in a new therapeutic era: Recontextualising the lived experience , 2018, Journal of clinical nursing.
[17] M. Harris. Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. , 2017, The International journal on drug policy.
[18] L. Elliott,et al. The lived experience of interferon-free treatments for hepatitis C: A thematic analysis. , 2016, The International journal on drug policy.
[19] D. Grossoehme,et al. Analyzing longitudinal qualitative data: the application of trajectory and recurrent cross-sectional approaches , 2016, BMC Research Notes.
[20] David A. Rolls,et al. Hepatitis C transmission and treatment as prevention - The role of the injecting network. , 2015, The International journal on drug policy.
[21] A. Gifford,et al. Resolute efforts to cure hepatitis C: Understanding patients’ reasons for completing antiviral treatment , 2015, Health.
[22] J. Arnsten,et al. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment. , 2015, Drug and alcohol dependence.
[23] M. Stepanova,et al. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life , 2015, Alimentary pharmacology & therapeutics.
[24] Z. Younossi,et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment , 2015, Therapeutic advances in gastroenterology.
[25] L. Henry,et al. Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens , 2015, Alimentary pharmacology & therapeutics.
[26] M. Guha. The Wiley-Blackwell Encyclopedia of Health, Illness, Behavior and Society , 2014 .
[27] D. Semela,et al. “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis , 2014, BMC Infectious Diseases.
[28] M. Hellard,et al. Eradication of hepatitis C infection: The importance of targeting people who inject drugs , 2013, Hepatology.
[29] M. Kinder. The Lived Experience of Treatment for Hepatitis C , 2009, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.
[30] M. Harris. Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis. , 2009, Sociology of health & illness.
[31] Carla Treloar,et al. The Lived Experience of Hepatitis C and its Treatment Among Injecting Drug Users: Qualitative Synthesis , 2009, Qualitative health research.
[32] Patricia Taylor-Young,et al. The Multidimensional Burden of Hepatitis C and Its Treatment: A Case Study , 2009, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.
[33] C. Treloar,et al. Resilient Coping , 2008, Journal of health psychology.
[34] D. Vlahov,et al. Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.
[35] C. Treloar,et al. Chronic Illness Experiences, Clinical Markers and Living with Hepatitis C , 2007, Journal of health psychology.
[36] K. Sheppard,et al. The Patient Experience of Treatment for Hepatitis C , 2006, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.
[37] D. Battistutta,et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. , 2006, Journal of pain and symptom management.
[38] V. Braun,et al. Using thematic analysis in psychology , 2006 .
[39] C. Treloar,et al. The Experience of Interferon-Based Treatments for Hepatitis C Infection , 2005, Qualitative health research.
[40] R. Hays,et al. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment , 2005, Hepatology.
[41] Belinda Crockett,et al. “Eyes Wide Shut”: Narratives of Women Living with Hepatitis C in Australia , 2004, Women & health.
[42] David Calvey. Longitudinal Qualitative Research: Analyzing Change Through Time , 2004 .
[43] Johnny Saldaña,et al. Longitudinal Qualitative Research: Analyzing Change Through Time , 2003 .
[44] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[45] V. Coates,et al. Diagnosed with Hepatitis C: a descriptive exploratory study. , 2001, International journal of nursing studies.
[46] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[47] P. Marcellin,et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.
[48] C. Dolea,et al. World Health Organization , 1949, International Organization.